Inhalopédia | Inhalers

Class
- Inhaled corticosteroid (ICS)
  Long-acting beta-2 agonist (LABA)
Active ingredient
- Mometasone furoate
- Indacaterol (as acetate)
Device
- Breezhaler®
Inhalers techniques and maintenance
Age
- 12 +
Typical use
- Asthma
  uncontrolled on low dose ICS
Asthma management principles
- COPD (off-label)
  in addition to a LAMA, when exacerbating on dual bronchodilation (LAMA/LABA)
COPD management principles
Marketed strength
- 80/150 mcg
- 160/150 mcg
- 320/150 mcg
Number of doses
- 30 capsules
Dose indicator
- Yes | Number of capsules
Usual adult dosage
- Low | 80/150 mcg – 1 inh QD
  Medium | 160/150 mcg – 1 inh QD
  High | 320/150 mcg – 1 inh QD
ICS dosing
Usual pediatric dosage
- 12-17 years
  See adult dosage
ICS dosing
Required inspiratory flow
- > 50 L/min
  Low internal resistance (R1)
Inspiratory flows
Public coverage
- MN | Open/Regular Benefit
  All provinces except MN – YT | Restricted Benefit with criteria
  YT | Not a Benefit
Provincial coverage criteria
Advantages
- Low cost
- Once daily dosing
- Low internal resistance (less effort required for inhalation)
- Clear capsule which ensures complete inhalation
Disadvantages
- Capsule handling required
- The capsule may get stuck while rotating during inhalation
- Capsule may be ingested
Side effects

Product monograph

Download

Atectura®